This policy uses a cascade testing approach with TSH as the preferred first-line test for most clinical scenarios; follow-up or reflex tests (e.g., fT4, fT3, total T3) are reimbursed when TSH is abnormal or when specific conditions require direct thyroid hormone monitoring (for example, suspected central hypothyroidism, thyrotoxicosis, or pregnancy-related management). The policy retains specific frequency limits for monitoring: TSH up to once every 6 weeks for many diagnostic and dose-adjustment situations and TSH every 3 months for immune reconstitution or transplant-related monitoring. (Policy reorganized to emphasize cascade testing and updated 5/27/2026.)

Reimbursement is not allowed for testing of thyroxine binding globulin (TBG), thyrotropin releasing hormone (TRH), reverse T3, or T3 uptake, and routine thyroid function testing performed during a general exam without abnormal findings or other situations not specifically listed as covered may be denied. Overuse of non-guideline multi-test panels (e.g., routine reflex to free T4/fT3 without indication) can trigger utilization review or prior authorization scrutiny. Inclusion of a procedure code in the applicable service list does not guarantee payment; BCBSNC may request medical records to establish medical necessity.

Providers should document the clinical indication and pertinent clinical details in the medical record to support coverage decisions: examples include signs/symptoms of thyroid dysfunction, pregnancy status and trimester, relevant medications (e.g., amiodarone, lithium, tyrosine kinase inhibitors), history of thyroid disease or thyroid nodule, recent therapies (e.g., alemtuzumab), and timing of surgery or radioactive iodine when relevant. For pregnancy-related testing, laboratories and clinicians must use trimester- and method-specific reference ranges (and the policy prefers fT4 for some pregnancy monitoring scenarios). For postoperative differentiated thyroid cancer (DTC) surveillance, document timing of postoperative serum thyroglobulin (Tg) measurement (typically 6–12 weeks after total thyroidectomy), assay calibration (BCR457), and concurrent anti‑Tg antibody measurements when applicable.

Clinical-monitoring expectations specified by guideline concordance are reflected in coverage rules: for pregnant individuals on levothyroxine, monitor TSH every 4 weeks until mid-pregnancy and adjust dose to trimester-specific targets; in hypothalamic‑pituitary disease monitor FT4/TSH biannually in children and annually in adults; after treatment for primary hyperthyroidism expect closer monitoring (e.g., every 8 weeks during the first year). For patients receiving immune reconstitution therapy (e.g., alemtuzumab), TSH surveillance is recommended every 3 months for specified intervals and reflex testing with fT4/fT3 is allowed when TSH is abnormal.

Medical necessity documentation must be available on request. When records are requested to adjudicate a claim, include the indicated sign/symptom documentation, medication history, pregnancy status/trimester, assay methods/reference ranges, and any specialty guidance or rationale supporting nonstandard testing (for example, direct fT4 monitoring in secondary hypothyroidism). Benefits and eligibility remain determined by the member's contract and subscriber certificate in effect when services were rendered.

Key provider actions and risks to avoid: do not order or expect reimbursement for TBG, TRH, reverse T3, or T3 uptake; avoid ordering broad free thyroid hormone panels as first‑line screening in asymptomatic adults—start with TSH unless specific indications apply; recognize that some T3 and reverse T3 assays have significant analytic variability and limited clinical utility, which the policy cites as rationale for not covering routine use of these tests. Providers should consult the policy's coding section when submitting claims (including recent billing updates) and be prepared to supply supporting documentation if requested.

Universal screening for thyroid dysfunction in asymptomatic, nonpregnant adults is not recommended by USPSTF and is not considered routine care under this policy. Targeted testing is supported for individuals with risk factors or clinical signs listed in guideline sources (e.g., ATA/AACE/NICE), and the policy states providers should follow those guidance statements when deciding to test.

When testing is indicated, follow a TSH-first strategy: measure TSH alone for most adults when secondary thyroid disease is not suspected; if TSH is above the reference range, measure fT4 in the same sample; if TSH is below the reference range, measure fT4 and fT3 in the same sample, per NICE and other guideline excerpts included in the policy. Children and patients with suspected secondary (central) hypothyroidism should have both TSH and fT4 measured initially.

Guideline excerpts summarized in the policy also emphasize avoiding routine population-based or well-visit TSH screening in asymptomatic adults and recommend against routine measurement of calcitonin in pregnancy for thyroid nodules due to unclear benefit. The SMFM specifically recommends against screening asymptomatic pregnant individuals for subclinical hypothyroidism.

The policy aligns with society guidance to limit thyroid antibody testing to situations where it will inform management (e.g., TPOAb in subclinical hypothyroidism or recurrent miscarriage; TRAb in pregnant patients with prior Graves’ disease), and it restricts routine antibody testing to once every 3 years unless clinically indicated otherwise.

Guidance from the ASCP and other societies stresses appropriate initial evaluation: start with TSH and add free T4 for confirmation rather than ordering multiple tests at the outset. Studies cited in the policy show limited clinical utility and assay variability for T3 and reverse T3, supporting the policy’s stance to avoid routine use of those assays.

Follow guideline-derived, scenario-specific coverage criteria contained in the policy. Examples include: screening TSH for women seeking infertility care and for pregnant women with risk factors; measurement of TRAb in pregnant patients with prior Graves’ disease at initial testing and at defined gestational windows if elevated; and newborn screening for congenital hypothyroidism using blood spot testing 2–5 days after birth.

For initial adult evaluation of suspected thyroid disease, begin with serum TSH; add fT4 when TSH is abnormal and consider fT3 when TSH is low or thyrotoxicosis is suspected. Repeat mildly abnormal TSH values per society guidance (1–3 months) when appropriate prior to more extensive evaluation.

In differentiated thyroid cancer (DTC) management, the ATA-recommended approach is reflected: measure postoperative serum thyroglobulin (Tg) 6–12 weeks after total thyroidectomy while on thyroid hormone therapy (or after TSH stimulation), use assays calibrated to BCR457 where possible, and measure Tg and anti‑Tg antibodies together; follow-up Tg testing every 6–12 months in the initial period is allowed as clinically indicated.

For central hypothyroidism, the policy requires combined measurement of FT4 and TSH for diagnosis and confirms that CeH should be established by persistently low FT4 with inappropriately low/normal TSH on at least two separate determinations before labeling as central disease; monitoring frequency is adjusted by age (biannual in children, annually thereafter).

Therapy-monitoring recommendations from NICE and British Columbia guidelines are incorporated for interval guidance: adults on levothyroxine are typically monitored with TSH every 3 months until stable and then yearly; antithyroid drug and post-radioiodine monitoring also follow guideline-specified intervals.

The policy incorporates multiple society recommendations to clarify when direct fT4/fT3 monitoring is appropriate without prior abnormal TSH. Examples include suspected secondary (central) hypothyroidism, children and young people, and specific pregnancy scenarios. NICE’s testing cascade (TSH first, reflex to fT4/fT3 as indicated) is explicitly referenced and used to inform reimbursement logic.

For pregnant patients, guideline-derived monitoring is specified: target TSH ranges by trimester are applied, and when treating hyperthyroidism with antithyroid drugs the policy follows guidance to monitor fT4/TT4 and TSH approximately every 4 weeks during treatment. TRAb measurement timing in pregnancy for prior Graves’ disease is also reflected.

The policy follows ATA recommendations for DTC surveillance and also recognizes the ATA position that routine Tg/TgAb measurement is not recommended during active surveillance for low-risk patients, aligning coverage with guideline-based intervals or discontinuation when a sustained excellent response is documented (e.g., 5–8 years).

British Columbia and NICE monitoring intervals inform the policy’s covered frequency statements for levothyroxine titration, antithyroid drug monitoring, and special‑risk medication monitoring (e.g., amiodarone, lithium).

Overall, providers should apply these guideline-derived monitoring intervals when documenting medical necessity for covered tests.

Policy updates reorganized the When Covered criteria to use a cascade-based approach, reaffirming that TSH remains first-line for most scenarios while specifying when direct fT4/fT3 monitoring is appropriate (e.g., secondary hypothyroidism or active fT4 monitoring needs). The 5/27/2026 revision explicitly added criteria for follow-up testing after abnormal TSH and for fT4-only monitoring in secondary hypothyroidism.

Providers should be aware that the policy does not specify a routine prior authorization requirement for thyroid testing; however, non-guideline testing patterns (for example, ordering broad free hormone panels instead of following the TSH-first cascade) may be subject to utilization review or require prior authorization per payer processes. CPT/Coding updates (including addition of CPT 83520 to the billing/coding section) are noted in the policy implementation history—refer to the coding section when submitting claims.

The policy highlights situations of potential overuse: repeated or routine measurement of T3 or reverse T3 has limited analytic validity and clinical utility and is not covered for routine monitoring; ordering multiple tests for initial evaluation rather than starting with TSH may be considered unsupported practice and could lead to denial.

Documentation expectations tied to eligibility and benefits are emphasized: coverage is determined by the group contract and subscriber certificate in effect, and when BCBSNC requests records to determine medical necessity, include the clinical indication, relevant history, medication or therapy details, pregnancy status/trimester, and assay/reference-range information to support the claim.

Testing explicitly not reimbursed includes TBG, TRH, reverse T3, and T3 uptake; the policy states these tests are excluded from coverage under any circumstances described in the document. The decision reflects assay limitations and lack of evidence for clinical utility in routine settings.

Analytic validity concerns for T3 and reverse T3 are cited in the policy background and guidelines sections—studies show substantial disagreement between immunoassays and reference methods (LC/MS/MS) and inconsistent relationships between reverse T3 and thyroid status, supporting the noncoverage stance for these assays.

Providers should avoid ordering these excluded tests and should instead follow the cascade approach beginning with TSH and reflexing to fT4/fT3 or other indicated tests only when clinically justified and documented.

When submitting claims for covered thyroid studies, be prepared to provide documentation of the clinical indication, relevant symptoms or risk factors, medication history, pregnancy status, and assay-specific reference ranges; BCBSNC may request medical records to establish medical necessity and to adjudicate reimbursement.

Routine thyroid function testing during a general exam without abnormal findings is considered not medically necessary unless a listed indication is present. This aligns with USPSTF and ASCP recommendations against population screening in asymptomatic adults and with SMFM guidance advising against screening asymptomatic pregnant individuals for subclinical hypothyroidism.

The policy notes limited utility of measuring T3 in patients on levothyroxine and documents assay variability that undermines value for routine monitoring; similarly, reverse T3 measurement cannot reliably distinguish hypothyroidism from euthyroidism and is therefore not covered.

Antibody testing is allowed in specified clinical contexts (e.g., TPOAb for subclinical hypothyroidism or recurrent miscarriage; TRAb in pregnant patients with prior Graves’ disease) and is restricted to once every 3 years when used outside of known autoimmune thyroid disease to limit unnecessary repeat testing.

Providers performing testing for thyroid cancer surveillance should follow ATA guidance for postoperative Tg/TgAb timing and assay considerations; routine Tg monitoring during active surveillance of low-risk DTC is not recommended by the ATA and is reflected in coverage guidance.

Thyroid hormones regulate growth, development, and metabolic homeostasis. Serum TSH is the preferred initial test for evaluating thyroid function; abnormal TSH results guide reflex testing (for example, fT4 when TSH is high; fT4 and fT3 when TSH is low). Pregnancy, certain medications, and specific clinical scenarios alter testing interpretation and recommended monitoring intervals.